Windlas Biotech Ltd
Windlas Biotech Ltd (WINDLAS) last reported results for the quarter ended Mar 2026, with sales of ₹238 crore and net profit of ₹16 crore. The stock last traded at ₹1,022, a market capitalisation of ₹2,109 crore, on a P/E of 31.7. Over the past 52 weeks the stock has ranged between ₹697 and ₹1,182. Figures are as of 6 Oct 2026 and are not real time.
Windlas Biotech Ltd share price and key metrics
- Current price
- ₹1,022
- Market cap
- ₹2,109 cr
- Stock P/E
- 31.7
- Book value
- ₹275
- ROE
- 12.2%
- ROCE
- 15.9%
- Dividend yield
- 0.63%
- 52w high / low
- 1182/697
Metrics as of 6 Oct 2026. Not real time.
Track Windlas Biotech Ltd
Cruxal reads every Windlas Biotech Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Windlas Biotech Ltd growth and returns
- 10 Years
- %
- 5 Years
- 16%
- 3 Years
- 21%
- TTM
- 19%
- 10 Years
- %
- 5 Years
- 16%
- 3 Years
- 17%
- TTM
- 9%
- 10 Years
- %
- 5 Years
- 23%
- 3 Years
- 40%
- 1 Year
- 11%
- 10 Years
- %
- 5 Years
- 12%
- 3 Years
- 13%
- Last Year
- 12%
Windlas Biotech Ltd quarterly results
In the quarter ended Mar 2026, sales were ₹238 cr, up 17.2% from ₹203 cr a year earlier. Net profit was ₹16 cr, up 0.0% year on year.
| ₹ crore | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 175 | 187 | 195 | 203 | 210 | 222 | 233 | 238 |
| Expenses | 154 | 164 | 170 | 177 | 184 | 194 | 209 | 213 |
| Operating profit | 21 | 23 | 25 | 26 | 27 | 29 | 24 | 25 |
| OPM % | 12% | 12% | 13% | 13% | 13% | 13% | 10% | 11% |
| Other income | 4 | 5 | 4 | 5 | 5 | 4 | 5 | 4 |
| Interest | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 6 | 6 | 7 | 8 | 7 | 8 | 8 | 8 |
| Profit before tax | 18 | 20 | 20 | 21 | 23 | 24 | 20 | 20 |
| Tax % | 26% | 23% | 23% | 22% | 24% | 25% | 25% | 21% |
| Net profit | 13 | 16 | 16 | 16 | 18 | 18 | 15 | 16 |
| EPS (₹) | 6.45 | 7.49 | 7.45 | 7.77 | 8.43 | 8.45 | 7.12 | 7.58 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Windlas Biotech Ltd annual results
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 352 | 307 | 329 | 428 | 466 | 513 | 631 | 760 | 904 |
| Operating profit | 39 | 38 | 34 | 55 | 52 | 60 | 78 | 94 | 105 |
| OPM % | 11% | 12% | 10% | 13% | 11% | 12% | 12% | 12% | 12% |
| Net profit | 11 | 64 | 16 | 16 | 38 | 43 | 58 | 61 | 66 |
| EPS (₹) | 20.04 | 99.55 | 25.28 | 24.69 | 17.48 | 20.04 | 27.98 | 29.10 | 31.49 |
TTM is the trailing twelve months to the most recent quarter.
Windlas Biotech Ltd balance sheet
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 6 | 6 | 6 | 6 | 11 | 10 | 10 | 10 | 11 |
| Reserves | 119 | 187 | 203 | 193 | 384 | 392 | 440 | 495 | 570 |
| Borrowings | 57 | 32 | 29 | 32 | 7 | 5 | 4 | 33 | 35 |
| Other liabilities | 107 | 73 | 100 | 65 | 90 | 122 | 173 | 222 | 291 |
| Total liabilities | 290 | 298 | 338 | 296 | 491 | 529 | 626 | 760 | 907 |
| Fixed assets | 86 | 64 | 70 | 96 | 91 | 109 | 179 | 223 | 213 |
| CWIP | 53 | 5 | 0 | 0 | 8 | 15 | 6 | 5 | 60 |
| Investments | 23 | 122 | 116 | 23 | 65 | 107 | 173 | 223 | 268 |
| Other assets | 128 | 107 | 152 | 177 | 327 | 298 | 268 | 308 | 366 |
| Total assets | 290 | 298 | 338 | 296 | 491 | 529 | 626 | 760 | 907 |
As reported by the company. Total assets equal total liabilities by construction.
Windlas Biotech Ltd cash flow
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 35 | 19 | 25 | 11 | 9 | 61 | 109 | 68 | 105 |
| Cash from investing | -11 | -7 | -14 | -20 | -155 | -14 | -92 | -74 | -92 |
| Cash from financing | -26 | -6 | -5 | 1 | 130 | -44 | -15 | 1 | -13 |
| Net cash flow | -2 | 6 | 5 | -8 | -15 | 3 | 2 | -5 | 0 |
| Free cash flow | 10 | 10 | 10 | 6 | -6 | -9 | 71 | 16 | 37 |
| CFO / operating profit | 102% | 81% | 113% | 33% | 34% | 117% | 163% | 95% | 115% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Windlas Biotech Ltd operating ratios
| Per year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| ROCE % | — | 15% | 12% | 19% | 15% | 14% | 18% | 17% | 16% |
| Debtor days | 69 | 73 | 71 | 68 | 87 | 83 | 79 | 80 | 92 |
| Inventory days | 54 | 36 | 85 | 55 | 71 | 84 | 57 | 63 | 40 |
| Days payable | 130 | 110 | 143 | 53 | 76 | 98 | 121 | 129 | 156 |
| Cash conversion cycle | -7 | -1 | 13 | 70 | 81 | 69 | 15 | 14 | -24 |
| Working capital days | -30 | -12 | 2 | 40 | 85 | 71 | 32 | 17 | 14 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Windlas Biotech Ltd shareholding pattern
Promoters held 63.31% at Jun 2026, up from 62.34% at Jun 2025. FIIs 2.04% and DIIs 9.84%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 62.51% | 62.51% | 62.34% | 62.34% | 61.98% | 61.98% | 61.90% | 63.31% |
| FIIs | 2.00% | 1.55% | 1.52% | 1.44% | 1.11% | 0.93% | 0.60% | 2.04% |
| DIIs | 9.58% | 10.26% | 10.89% | 11.22% | 11.44% | 11.44% | 11.80% | 9.84% |
| Public | 25.91% | 25.67% | 25.25% | 25.01% | 25.48% | 25.64% | 25.69% | 24.80% |
| No. of shareholders | 45,706 | 46,590 | 46,383 | 45,887 | 45,433 | 45,461 | 44,769 | 44,996 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Windlas Biotech Ltd corporate filings
- Certificate under Regulation 74 (5) of the SEBl (Depositories and Participants) Regulations, 2018 for the Quarter ended September 30, 2026Company Updatelow impact
- Intimation of Closure of Trading WindowInsider Trading / SASTlow impact
- Windlas Biotech Ltd schedules analyst and institutional investor meetingsCompany Updatelow impact
Cruxal's analysis: Windlas Biotech Ltd has issued an intimation regarding scheduled meetings with analysts…
Read the full analysis - Windlas Biotech Reports Record Q1 FY27 Revenue of INR248 Crore with 18% YoY GrowthCompany Updatehigh impact
Cruxal's analysis: Windlas Biotech Limited delivered its 14th consecutive quarter of record revenue…
Read the full analysis - Windlas Biotech Ltd releases audio recording of Q1 conference callCompany Updatelow impact
Cruxal's analysis: Windlas Biotech has made the audio recording of its Q1 conference call available to the…
Read the full analysis - Windlas Biotech Reports Record Q1 FY27 Revenue of 248 Crore with 37% YoY Adjusted PAT GrowthCompany Updatehigh impact
Cruxal's analysis: Windlas Biotech Limited achieved its 14th consecutive quarter of record revenue, reaching…
Read the full analysis - Windlas Biotech Reports Strong Q1 FY27 Performance with 18% YoY Revenue Growth and Record Quarterly RevenueCompany Updatehigh impact
Cruxal's analysis: Windlas Biotech Limited has announced its Q1 FY27 financial results, achieving a record…
Read the full analysis - Windlas Biotech Limited Reports Strong Q1 FY27 Financials with Revenue of 248.10 crore and PAT of 17.65 croreBoard Meetinghigh impact
Cruxal's analysis: Windlas Biotech Limited reported a robust performance for the quarter ended June 30…
Read the full analysis - Windlas Biotech schedules conference call for Q1 FY2027 financial resultsCompany Updatelow impact
Cruxal's analysis: Windlas Biotech has announced a conference call to discuss its financial performance for…
Read the full analysis - Windlas Biotech schedules conference call for June 30, 2026 quarterly financial resultsCompany Updatelow impact
Cruxal's analysis: Windlas Biotech Ltd has issued an intimation regarding a conference call to discuss its…
Read the full analysis - Windlas Biotech to Convene Board Meeting on August 10, 2026, to Approve Q1 FY27 Financial ResultsBoard Meetinglow impact
Cruxal's analysis: Windlas Biotech Limited has announced that its Board of Directors will convene a meeting…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.